<h3>Objective:</h3> We report on three individuals with semantic variant primary progressive aphasia (svPPA) whose post-mortem pathology was consistent with diffuse neocortical Lewy body disease (LBD). We believe this is a heretofore unrecognized phenotype of LBD. <h3>Background:</h3> The present conception of primary dementias pairs clinical syndromes with neuropathologies, proven on necropsy or indirectly implicated by biomarkers. Each pairing is a clinicopathological entity. There is an increasing focus in the field of neurodegenerative disease to better characterize clinicopathological disorders, so as to target research and treatment approaches. SvPPA clinically manifests with progressive loss of semantic knowledge and is commonly associated with TDP-43 type C proteinopathy as well as Alzheimer’s(AD) and other tau pathologies. We report on three instances of svPPA associated with LBD pathology. We believe this is the first such report in the literature. <h3>Design/Methods:</h3> Our institution’s brain bank was queried for clinicopathological cases with a clinical diagnosis of svPPA and neuropathologic diagnosis of LBD. Three cases met the international consensus criteria for svPPA and were included in this study. <h3>Results:</h3> Three males aged 60–76 satisfied our inclusion criteria. Two subjects had significant temporal atrophy, and one had substantia nigral pallor. DAT scan was available in one subject, which was a negative study. All subjects fit the neuropathological consensus criteria for LBD with a diffuse neocortical distribution. In addition, all subjects had moderate vascular pathology and AD pathology (2-high ADNC, 1-intermediate). One case was also found with limbic associated Stage 1 TDP-43 proteinopathy. <h3>Conclusions:</h3> Here we propose a novel language variant of Lewy body disease. Although rare, LBD should be included as a differential diagnosis in individuals with svPPA. In the future, characterizing phenotypes of LBD will assist in more precise targeting of research and treatment strategies. <b>Disclosure:</b> Dr. Merhi has nothing to disclose. Anna C Sullivan has nothing to disclose. Miss Bhavaraju has nothing to disclose. Dr. Walker has nothing to disclose. Dr. Bieniek has nothing to disclose. Dr. Abdullah has nothing to disclose. Dr. Salardini has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen. The institution of Dr. Salardini has received research support from NIH/NIA. The institution of Dr. Salardini has received research support from Taylor Family. Dr. Salardini has received publishing royalties from a publication relating to health care. Dr. Rini has nothing to disclose. An immediate family member of Dr. Parker has received personal compensation for serving as an employee of Rochal Industries, Rochal Parners. An immediate family member of Dr. Parker has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Sanara Med Tech. An immediate family member of Dr. Parker has stock in Sanara Med Tech. An immediate family member of Dr. Parker has stock in Rochal Industries. An immediate family member of Dr. Parker has stock in Rochal Parnters. The institution of Dr. Parker has received research support from Texas Alzheimer’s Research and Care Consortium. The institution of an immediate family member of Dr. Parker has received research support from Rochal Industries. An immediate family member of Dr. Parker has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Parker has received publishing royalties from a publication relating to health care. Dr. Parker has received personal compensation in the range of $500-$4,999 for serving as a Grand Rounds Speaker with Univ of Texas Tyler. An immediate family member of Dr. Parker has received personal compensation in the range of $0-$499 for serving as a NIH Review Committees Member with NIH. An immediate family member of Dr. Parker has a non-compensated relationship as a Chairwoman of the Board - Ann Salamone with BioMed SA that is relevant to AAN interests or activities.